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Abstract.  Tenascin is a large extracellular matrix 
(ECM) glycoprotein found in restricted tissue locations 
in the adult organism.  It is copiously synthesized in 
regenerative organs or regenerating tissues and by cer- 
tain tumors. We have analyzed the expression of tenas- 
cin in human long term bone marrow cultures as well 
as in cryostat sections of native bone marrow and 
found it strongly expressed by the stromal cells of the 
microenvironment. Two different protein subunits of 
280 and 220 kD were detected by immunoblotting. 
These two forms are derived most likely from two 
different mRNA splice variants of 6 and 8 kb detected 
by Northern blotting. The in vivo analysis of cryostat 
sections showed a codistribution with other ECM mol- 
ecules such as fibronectin and collagen type III in the 
microenvironment surrounding the maturing hemato- 
poietic ceils.  Using two independent cell adhesion as- 
says tenascin could be shown to function as a  cyto- 
adhesive molecule for hematopoietic cells.  These data 
suggest a  direct involvement of tenascin in the reten- 
tion of hematopoietic progenitor cells in the stroma. 
T 
HE hematopoietic microenvironment, which is known 
to be essential for hematopoietic stem cell prolifera- 
tion and differentiation, consists of different kinds of 
stromal cells and an extracellular matrix (ECM) ~ (15, 40). 
Adhesive cell-cell and cell-matrix interactions are thought 
to play a critical role in the specific homing of hematopoietic 
progenitor cells to the bone marrow and the controlled re- 
lease of  mature cells into the peripheral blood stream (5, 21). 
Many data concerning the importance of  the marrow stromal 
cells and their ECM  for hematopoiesis are derived from 
studies with long term marrow cultures (LTMC), in which 
an adherent layer of stromal cells can support hematopoiesis 
in vitro for months (14, 19). In these LTMC, direct cell-cell 
contact between hematopoietic progenitor cells and stromal 
cells as well as specific interactions with components of the 
ECM has been shown to be necessary for hematopoietic cell 
maturation (3, 5,  13). 
Within the ECM, heparan sulfate proteoglycans can bind 
hematopoietic growth factors and present them to the hema- 
topoietic precursors (22, 34). Three other extracellular ma- 
trix components are known to be involved in hematopoietic 
cell  attachment.  Many  hematopoietic  cell  lines  bind  to 
fibronectin, a wide-spread ECM molecule (20). The attach- 
ment  of developing  erythrocytes to  fibronectin  is  devel- 
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opmentally regulated (32,  33).  Thrombospondin, another 
ECM molecule with a ubiquitous distribution, mediates the 
adhesion of  pluripotent and committed progenitor cells (27). 
An adhesive ECM component with a specific restriction to 
the bone marrow is hemonectin, which has been character- 
ized in the rabbit (6). Binding to hemonectin has been shown 
to be developmentally controlled for granulocytic cells (7). 
Another defined ECM protein with adhesive properties is 
tenascin. This molecule shows a restricted expression pat- 
tern both during development and in the adult organism (17, 
30). In the mouse embryo, tenascin could be detected at sites 
of epithelial-mesenchymal interactions which are of utmost 
importance during normal organ development (2,  11, 43). 
Despite the restricted expression pattern reported for tenas- 
cin which implicated important functions in various mor- 
phogenetic events, it was recently shown that mutant mice 
lacking tenascin expression develop normally (36).  This un- 
expected finding refutes the vital role of tenascin during em- 
bryogenesis. In the adult organism tenascin expression is 
mainly found in skin and gut, both highly regenerating organ 
systems, along basement membranes of various epithelia, as 
well as at sites of wound healing and in certain tumors (1, 
11, 26, 28). It remains to be seen if adult tissues are also not 
affected by the loss of tenascin in the mutant mice. 
Tenascin consists of six similar subunits linked to their 
amino terminal ends by disulfide bonds (18). Due to differen- 
tial splicing, the length of the subunits may vary and subunit 
composition can be tissue-specific (23,  41).  Tenascin has 
been shown to interact with an integrin-like receptor (4), but 
also seems to bind particularly to proteoglycans (24). 
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sible role in cell attachment in the human bone marrow was 
analyzed both ex vivo and in LTMC. Using immunofluores- 
cence staining and Western and Northern blotting tenascin 
is demonstrated to be a major ECM protein of this highly 
reproductive tissue. Two different and independent cell adhe- 
sion assays suggest a specific adhesive function of tenascin 
for cell-matrix interactions between stromal cells and hema- 
topoietic progenitor cells. 
Materials and Methods 
Bone Marrow Samples 
Bone marrow (BM) samples taken from the sternum of nonhematologic  pa- 
tients undergoing thoracic surgery  after informed consent were kindly 
provided by Professor Seboldt, University Surgery Clinic, Tiibingen. These 
samples were mainly used for cryostat sections. FOr the establishment of 
LTMC normal BM aspirates were derived from consenting donors of BM 
transplants  from the Bone  Marrow  Transplantation  Center,  University 
Medical Clinic, Tfibingen. 
Establishment of  Long Term Bone Marrow Cultures 
Mononuelear cells were obtained from BM aspirates diluted with PBS after 
density gradient centrifugation on a Percoll cushion (1.077 mg/mi). For im- 
munofluorcsccnce  staining,  stromal  cell  layers  were  grown  from  106 
mononuclear ceils in 24 well plates, either on plastic or on glass coverslips, 
in 1 mi RPMI-1640 culture medium supplemented with 12.5% horse se- 
rum,  12.5%  FCS  and  10-~M  hydrocortisone (Dexter  conditions).  For 
comparison, a medium according to Whitlocke/Witte containing 5 % FCS 
and 5  ×  10-SM mercaptoethanol was used to establish LTMC mainly sup- 
porting lymphopoiesis. For blotting procedures and the indirect cell adhe- 
sion assay, BM cells were seeded at a density of 5  x  106 mononuelear cells 
in 5  ml in tissue culture flasks (25  cm  2) or in 2  ml in 35-ram dishes, 
respectively. For these studies the medium according to Dexter was used. 
The media were changed completely every week. 
Cell Culture 
The following cell lines kindly provided by Dr. H. I. Bdhring (University 
of Tfibingen, FRG) were used for cell attachment essays: HL60 (promyelo- 
cytie), KGIa (myeloblastic), and K562 (erythroleukemic cell line). All these 
cell lines were grown in RPMI-1640 culture medium supplemented with 
10% FCS. The human melanoma cell line SK-MEL-28, which was used for 
tenascin purification, was obtained from American Type Culture Collection 
(Rockville,  MD).  This  cell  line  was  propagated  in  minimal  essential 
medium with HBSS supplemented with nonessential amino acids, L-gin- 
tamine, sodium pyruvate, and  10%  FCS.  Serum was omitted from this 
medium  when the cells  were used to  collect conditioned medium  for 
purification of tenasein. 
Antibodies 
For the unambiguous detection of tenascin in the bone marrow, different 
monoclonal and polyclonal antibodies were applied. A  polyelonal anti- 
human tenascin antiserum was purchased from Telios Pharmaceuticals (San 
Diego, CA). Two monoclonal antibodies against human tenascin, clone EB2 
and clone DB'/, were commercially available from BIOHIT OY, Helsinki, 
Finland. Two monoclonal antibodies against mouse tenascin, MTrd and 
MTn24, which cross-react with human tenascin, were a kind gift of Dr. Pe- 
ter  Ekblom,  University of Uppsala,  Sweden.  The human blond vessel 
specific monoclonal antibody Rbl0,  which reacts  exclusively with  en- 
dotbelial cells of  various tissues tested (e.g., tonsils, appendix, lymph nodes 
and Peyer's patches) was a  generous gift of Dr.  Rupert Hallmann, Max 
Planck group for rhe~umatology, Erlangen, FRG.  The antiserum against 
EHS-tumor laminin which cross-reacts with human laminin has been de- 
scribed earlier (25). The other antibodies were purchased from Dianova, 
Hamburg, FRG (mouse anti-human/~l-integrin), Telios Pharmaceuticals 
(rabbit anti-human flbronectin), Dunn,  Asbaeh, FRG (goat anti-human 
collagen type Ill), and Dako, Hamburg, FRG (horseradish peroxidase-con- 
jngated rabbit anti-mouse immunoglobulins). 
Indirect Immunofluorescence 
BM samples were frozen in Tissue-Tek (Miles Scientific, Naperville, IL) by 
liquid nitrogen. 6-8-/~m slices were cut on a eryostat (Reichert and Jung, 
Heidelberg, FRG) and air-dried for at least 1 h. Both BM cryostat sections 
and stromal cells grown on coverslips  were fixed for 5 min in -20"C metha- 
nol. The fixed specimens were washed in PBS containing 0.1% albumin, 
and then incubated with the first antibody for 1 h in a moist chamber. For 
double immunofluorescence staining, the first antibodies, either an antise- 
rum from rabbit or from goat and a monoclonal antibody from either mouse 
or rat, were incubated simultaneously. After several washings, the bound 
antibodies were detected with a  FITC-conjugated anti-mouse or anti-rat 
second antibody and a rhodamine-conjugated anti-rabbit or anti-goat sec- 
ond antibody (Dianova, Hamburg, FRG) at a dilution of 1:200. The second 
antibodies were also simultaneously incubated. After washing with PBS, 
the specimens were mounted with elvanol embedding medium and photo- 
graphs  were taken  under  a  Zeiss  axiophot microscope equipped with 
epifluorescent  optics. Control stalnings were performed by omitting the first 
antibodies  and  no  fluorescence  staining  above  background  could  be 
detected. 
Immunoblotting 
Tenasein was extracted from LTMC in a buffer containing 150 mM NaC1, 
10 mM EDTA, 50 mM Tris-HC1, pH 7.4, 2 mM PMSF and 0.1% aprotinin. 
Using a cell scraper the adherent cells were scraped off, and after sonication 
the homogenate was kept on ice for one hour. After centrifugation the super- 
natant was reduced by boiling for 5  rain in Lacmmli buffer containing 
dithiotreitol.  The  protein  extract  was  separated  on  a  5-15%  SDS- 
polyacrylamide gradient gel and transferred onto nitrocellulose. Blocking 
of the filter was performed in a  solution containing 3% BSA and 0.05% 
Tween 20 for 3 h. The filter was then incubated with the monoclonal anti- 
human tenascin antibodies. Bound antibodies were detected with the peroxi- 
dase conjugated anti-mouse antibody and visualized by a  color reaction 
with H202  and 4-chloro-l-naphtol. For molecular mess determination a 
colored standard protein mixture (rainbow marker,  Amersham-Buehler, 
Braunschweig, FRG) was used. 
Northern Blotting 
Total RNA was extracted from pooled stromal cells which were trypsinized 
and then homogenized  in 4 M guanidinium isothiocyanate. The homogenate 
was forced through a 20-gauge needle several times to shear high molecular 
weight DNA.  The  RNA  was purified by  ultracentrifugation through a 
cesium chloride cushion. Around 5 #g of total RNA were obtained from 
106 cells. The total RNA was electrophoresed in a  1% agarose formalde- 
hyde  gel  (39).  Transfer  of  RNA  to  a  Hybond  N +  nylon  membrane 
(Amersbam-Buehler, Braunschweig, FRG)  was carried out by capillary 
blotting with 20× SSC according to the manufacturer's instructions. For hy- 
bridization, the human tenascin specific 2.2 kB eDNA probe HT-I1  (8), 
which was a generous gift of Dr. Lueiano Zardi, Genoa, Italy, was used. 
50 ng of the purified eDNA HT-11 were labeled with diguxigenin-ll-UTP 
(DIG) from Boehringer-Mannbeim, FRG, according to their instructions. 
Prehybridization of  the filter and hybridization with the DIG-labeled eDNA 
probe was carried out exactly according to an optimized hybridization and 
detection protocol for nonradioactive Northern blotting recently published 
by Engler-Blum et al. (16). After overnight hybridization at 68"C, the filter 
was washed several times at 68°C. Immunological detection of the bound 
DIG-labeled eDNA  was achieved with anti-DIG alkaline phosphatase- 
conjugated Fab fragments and AMPPD purchased from Boehringer-Mann- 
heim, FRG. After sealing the wet membrane in a hybridization bag the filter 
was exposed to Hyperfilm'~-MP (Amersham-Buehler) at room temperature 
for various times. The sizes of the mRNA detected were determined using 
a DNA molecular weight marker (Boehringer, Mannheim, FRG). 
Indirect Cell Adhesion Assay 
Freshly isolated BM mononuclear cells were incubated at 37°C in a plastic 
culture dish. After two hours of incubation the plastic nonadherent cells 
were removed after gentle agitation of the dish and seeded at a density of 
6  ×  105  ceils onto preformed confluent stromal cell layers in  35-ram 
dishes. The incubation with the stromal layers was done in the absence or 
presence of different antibodies. 10 tA of the respective antisera was added 
in each experiment. To evaluate if an antibody had an inhibitory effect on 
cell binding, the stroma nonadherent cells were removed after 2 h of  incuba- 
tion and assayed in semisolid 0.8 % methylcellulose cultures for their CFU- 
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phage colony  stimulating  factor  from Genzyme,  ICC,  Ismaning,  FRG; 
specific activity 3x  107 U/mg) and 50 U ml  -I of erythropoietin (CILAG, 
Sulzbach, FRG) were added to these cultures. After fourteen days of cul- 
ture,  formed colonies with more than fifty cells were counted. 
Tenascin Purification 
Human tenascin was purified from conditioned medium of  the SK-MEL-28 
cell line according to a recently published method of Saginati et al. (37). 
Briefly,  confluent cell layers of SK-MEL-28 were  fed with  serum free 
medium containing  1%  aprotinin to inhibit protein degradation.  Condi- 
tioned media for tenascin purification were completely replaced on day 7, 
14, 21, and 28. The collected and combined medium was filtered, the pH 
was corrected to pH 7.0, and the medium was then passed through a gelatin- 
Sepharose-4B column in order to remove fibronectin which is a main com- 
ponent  shed  into  the  medium.  Unbound  material  was  directly  passed 
through a hydroxylapatite column equilibrated with medium. Under these 
conditions tenascin bound to the column. After washing, the bound material 
could be ehited by a sodium phosphate linear gradient of 5-300 raM. The 
fractions containing tenascin were determined by immunoblotting with the 
monoclonal anti-human tenascin antibody EB2.6 % of polyethylene glycol 
(PEG) was added to the combined tenascin-containing fractions to remove 
high molecular mass contaminants. After centrifugatiun tenascin was pre- 
cipitated  from the supernatant by  increasing the PEG-concentration to 
12.8%. The centrifuged pellet containing the pure tenascin preparation as 
judged by silver staining was dissolved in 150 mM NaCI, 20 mM Tris-HCl, 
and aliquots were stored at  -20°C. 
Cell Attachment Assay 
Human fibronectin purchased from Telios (Biomol, Hamburg, FRG) and 
purified tenascin from the SK-MEL-28 cell line were immobilized onto 
plastic dishes by air-drying at room temperature. 2/~g of the proteins were 
used for each spot. Nonspecific binding of cells to plastic was prevented 
by blocking the culture dishes with a solution of 1 mg/ml HSA in RPMI- 
1610 medium. Cells in serum free medium were allowed to adhere to the 
immobilized proteins for 1 h at 37°C. Nonadherent cells were removed by 
gently rinsing the wells with warm PBS. Adherent cells were fixed for 20 
rain  with  3%  paraformaldehyde  and  stained  with  the  May-Griinwald 
Giemsa dye. Specific cell attachment was evaluated under a photomicro- 
scope. 
Results 
Expression of Tenascin in Long Term Bone 
Marrow Cultures 
BM stromal cells were grown on glass coverslips for at least 
3 wk before fixation and immunostaining with the anti-tenas- 
cin antibodies. The immunofluorescence staining showed a 
strong expression of tenascin in the adherent stromal cell 
layer no matter whether the ceils were grown under Dexter 
conditions favoring myelopoiesis as seen in Fig. 1 a or under 
Whitlocke/Witte  conditions  favoring  lymphopoiesis  (data 
not shown). In all cultures analyzed tenascin could be found 
in an extracellular meshwork. Double immunofluorescence 
staining of tenascin with other ECM molecules did not show 
an exact codistribution of these molecules in the stromal cell 
cultures. For example, the extracellular deposition of fibro- 
nectin (Fig.  1 b) could be shown to be different from that of 
tenascin (Fig.  1 a). 
The Western blot analysis  confirmed the  expression of 
tenascin by the adherent stromal layer. Using the combined 
monoclonal anti-human tenascin antibodies EB2 and DB7 a 
strong reaction of the high molecular mass band of 280 kD 
was observed in stromal cell extracts. In addition a weaker 
band of 220 kD could be detected in these extracts (Fig. 2, 
lane a). These two signals most probably correspond to two 
Figure 1. Immunolocalization of tenascin in LTMC. The micro- 
graphs  show a  double  immunofluorescence  staining  of  fixed 
stromal cells with an antibody against tenascin (a) and with an an- 
tiserum against fibronectin (b). The adherent stromal cells express 
both matrix components in an extracellular meshwork, but the den- 
sity of the extracellular fibrils is less for tenascin. Bar, 50 #m. 
different splice variants known for the tenascin molecule, al- 
though it cannot be excluded that the weaker 220-kD band 
represents a specific degradation product. To exclude that the 
anti-tenascin antibodies do not even slightly cross-react with 
fibronectin which is also strongly expressed in LTMC (Fig. 
1 b), 1.5/zg of purified human fibronectin was immunoblot- 
ted with either the combined monoclonal antibodies (Fig. 2, 
lane b) or the polyclonal anti-tenascin antiserum (data not 
shown). None of these antibodies showed any reaction with 
purified fibronectin antigen. 
Transcription of tenascin by BM stromal ceils was evalu- 
ated by Northern blot analysis. Total RNA of stromal cells 
was probed under high stringency conditions with the human 
tenascin-specific eDNA clone HT-11 which reacts with an 
unspliced region of  human tenascin. Under these conditions, 
both the 6-kb and the 8-kb messages of  tenascin, also present 
in other studied tissues (44), could be detected in the stromal 
cell cultures (Fig. 3). Yet, the 8-kb mRNA is more strongly 
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sis of tenascin  expression  in 
LTMC. Adherent  cells of an 
LTMC  were  extracted  by 
sonication  in  a  TBS-EDTA 
buffer. The cell  extract  (lane 
a) and  1.5  #g purified  fibro- 
nectin (lane b) were run under 
reducing  conditions  on  a 
5-15%  SDS-PAGE gradient 
gel.  Using a  combination  of 
the  monoclonal  antibodies 
EB2 and DB7, a strong expres- 
sion  of  tenascin  could  be 
found  in  the  cell  extract  of 
LTMC (lane a).  Two signals 
for  tenascin  could  be  seen, 
corresponding to the different 
splice  variants.  No signal  at 
all was visible in lane b, thus 
proving that the antibodies do 
not cross-react with fibronec- 
tin.  Relative molecular  mass 
markers  xl0  -3  are  indicated 
to the left of the lanes. 
expressed than the 6-kb mRNA, but this result is in con- 
gruence with the obtained Western blot data showing also a 
stronger expression of the higher molecular weight band. 
Tenascin Expression in Bone Marrow In Vivo 
We analyzed the expression of tenascin in vivo on cryostat 
sections of BM samples and found a  strong expression of 
this ECM protein in this tissue. Double immunofluorescence 
staining showed a codistribution of tenascin with fibronectin 
(Fig. 4, a  and b) and with collagen type III (Fig. 4,  c and 
d). This staining pattern of tenascin in the ECM surrounding 
the hematopoietic cells could be detected with the different 
specific polyclonai and monoclonal antibodies used (see Ma- 
terials and Methods), which were shown not to cross-react 
with fibronectin. A differential expression pattern was seen 
on BM cryostat sections for tenascin and the ~  chain of inte- 
grins (Fig. 4,  e and f). Tenascin could be detected at sites 
where ~  integrin was not present. This finding does not ex- 
clude that a member of the ~-integrin family can still serve 
as a  cellular receptor for tenascin in  the human BM, but 
there might be other tenascin receptors as well. 
In addition to its localization in the extracellular space of 
the maturing hematopoietic cells, tenascin was also found in 
close association with blood vessels of the BM. In longitudi- 
nal and in cross sections of blood vessels, tenascin could be 
clearly localized within the walls of the arterial blood vessels 
(Fig.  5,  a  and b). 
Inhibition of  Progenitor Cell Adhesion to Stromal 
Cells by Anti-Tenascin Antibodies 
To analyze adhesive properties of tenascin within the BM, 
Figure 3.  Northern  blot analysis of 
tenascin  in  LTMC. 8.8  #g of total 
RNA isolated from LTMC cells were 
used. The filter was hybridized with 
the 2.2-kb cDNA clone HT-11 which 
detects an unspliced region of  human 
tenascin.  Two bands of 8 and 6 kb 
representing tenascin splice variants 
can be detected.  The 8-kb band  is 
more prominently expressed than the 
6-kb message. Exposure time of the 
labeled filter was 30 min. 
the polyclonal antiserum against tenascin was used to inhibit 
cell binding between hematopoietic cells and a  preformed 
adherent  stromal  layer.  Freshly  isolated  BM  cells  were 
layered onto a preformed stroma in the presence or absence 
of the antiserum.  After an incubation time of 2 h, the non- 
adhering cells were transferred into semisolid colony assays 
for 14 d. In four independent experiments (Table I), we con- 
sistently found a significantly higher number of colonies in 
those cultures which were incubated with the anti-tenascin 
antiserum  as  compared  to  the  cultures  without  antibody 
treatment, thus providing evidence that the antiserum had an 
inhibitory  effect on  cell  binding  of committed progenitor 
cells. GM-CSF and erythropoietin were added to the colony 
assays as growth factors, but only CFU-GM could be de- 
tected at 14 d. This suggests that the anti-tenascin antiserum 
did not interfere with BFU-E binding to stroma. Because of 
the large known donor-donor variations in progenitor cell 
numbers of BM cells, the total number of committed precur- 
sor cells without incubation on a  stromal layer was deter- 
mined in four individual experiments and the percentage of 
formed colonies after incubation on stroma was calculated. 
Such a calculation allows the specific inhibition of progenitor 
cell binding by the anti-tenascin antiserum which was found 
in all experiments conducted to be compared. The difference 
between the cultures grown with anti-tenascin antiserum and 
without antibody was found to be 12.7%  +  1.9%  (n  =  4). 
In control experiments two different antibodies were used. 
The incubation with an antiserum against laminin, an ECM 
component also expressed by stromal cells, had no influence 
on progenitor cell binding (Table I, 1.1) thus showing that the 
presence of an antibody alone has no inhibitory effect. In 
contrast, with an antiserum against fibronectin which is also 
strongly expressed by the stromal cells, we observed an inhi- 
bition of 14.2 % of progenitor cell binding (Table I, 4.1). This 
inhibition is comparable to that found with the anti-tenascin 
The Journal of Cell Biology, Volume  123, 1993  1030 Figure 4. Distribution of tenascin compared with other molecules in the BM. Double immunofluorescence labeling of cryostat sections 
of human BM are shown. The staining was performed with the antiserum against tenascin (a, c, and e) and with antibodies against fibronec- 
tin (b), collagen type Ill (d), and/31-integrin (e). The extracellular tenascin which is found between the hematopoietic cells colocalizes 
both with fihronectin (a and b) and collagen type IlI (c and d). On the other hand the double labeling of tenascin with the monoclonal 
antibody against the/31-chain of integrins shows no absolute congruence of these two molecules. Tenascin can be seen strongly expressed 
at sites where the/31-chain is hardly visible. On the other hand, 131-chain expression is also found at sites where tenascin is not deposited 
(arrowhead). Bars, 50 ~m. antiserum, but with the anti-fibronectin antiserum also some 
BFU-E could be detected suggesting different modes of ac- 
tion of the two antisera used. 
Figure 5. Association of  tenascin with blood vessel walls. The dou- 
ble  immunofluorescence staining  with  the  endothelial  specific 
monoclonal antibody Rbl0 (a) and tenascin (b) in the cryostat sec- 
tion shows a strong signal in the smooth muscle layer of  the arterial 
vessel wails. This is seen in a longitudinal as well as in a cross sec- 
tion (arrows). The sinusoids which are not surrounded by a smooth 
muscle layer show a much weaker association with tenasein (arrow- 
head). Bar, 50 t~m. 
Table L 
Attachment of  Hematopoietic Cells to 
Immobilized Tenascin 
The inhibition experiments using the anti-tenascin antibod- 
ies represent an indirect method to determine a cytoadhesive 
function of tenascin. To show an adhesive property of this 
molecule in a direct way we purified human tenascin from 
the conditioned medium of the SK-MEL 28 melanoma cell 
line according to a procedure recently published by Saginati 
et al. (37). The higher molecular mass form of tenascin was 
mainly produced by the melanoma cells but also a weak sig- 
nal of the lower molecular mass form could be detected by 
immunoblotting (Fig. 6 a). Fibronectin which is also shed 
in large amounts into the culture medium is efficiently re- 
moved by the gelatin-sepharose column. This was evaluated 
by immunoblotting of 50/~g of our tenascin preparation with 
an anti-fibronectin antiserum. No fibronectin signal could be 
found,  suggesting  that  if there is  any contamination with 
fibronectin, it is less than 1:10,000, since we are able to de- 
tect five nanograms of purified fibronectin by immunoblot- 
ring with the anti-fibronectin antiserum. 
2 t~g of the tenascin preparation were spotted onto plastic 
dishes and allowed to air-dry. In Fig. 6, b and c, the specific 
binding of the hematopoietic cell lines HL60 and K562 to 
the  immobilized,  purified  matrix  components  is  shown. 
Only a weak background binding is seen outside the tenas- 
cin-coated areas. Freshly isolated, unfractionated BM cells 
also attached to tenascin but not as strong as the leukemic 
cell lines. We compared the binding properties of the hetero- 
geneous BM cells and the homogeneous cell lines to tenascin 
and to purified fibronectin by counting attached cells to rep- 
resentative mm  2. Only a quantitative, but not a qualitative, 
difference of the adhesive capacity could be found (Table II). 
Discussion 
In the adult organism, expression of tenascin is not ubiqui- 
Stromal nonadhering progenitors: 
Number of colonies formed* 
b) With cx-tenascin 
Number of  antibody treatment 
Donor  colonies per  a) Without antibody  or control anti-  % Inhibition| 
number  3  ×  105 cells)  treatment  body treatment  (difference  b-a) 
1  207  79 (38.4%)  110 (53.1%)  14.7 % 
2  340  7  (2.0%)  47  (13.8%)  11.8% 
3  320  10 (3.1%)  44 (13.6%)  10.5% 
4  222  38 (16.8%)  68 (30.6%)  13.8% 
CONTROLS 
1.1  207  79 (38.4%)  79 (38.4%)  0% 
4.1  222  38 (16.8%)  69 (31%)  14.2% 
Inhibition of progenitor cell attachment to BM stroma by anti-tenascin antibodies (1--4): evaluation of the nonadherent precursors in mixed committed progenitor 
colony assays. The results of four individual experiments (1--4) and appropriate control experiments (1.1:  anti-laminin; 4. i: anti-fibronectin)  are shown. 
* Numbers of colonies counted in duplicate assays. 
* Determination of the total progenitor cell number. 
§ Difference of the median percent colony formation in assays with and without antibody treatment calculated as the number of colonies grown from nonadhering 
cells after incubation on stromal layer divided by the total number of input progenitor cell  s times 100. 
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of leukemic lines to purified 
tenascin. Human tenasein  puri- 
fied from the SK-MEL 28 cell 
line  consists  mainly  of the 
higher  molecular  mass form 
as shown by imrnunoblotting 
(a). K562 cells (b) and HI.,60 
cells (c) were allowed to bind 
to immobilized human tenas- 
cin.  After  washing,  fixation 
and  staining, the border be- 
tween serum albumin-coated 
and the tenascin-coated areas 
is precisely outlined by spe- 
cifically attached  cells.  Bar, 
50 #m. 
tous but confined to certain tissues and organs (9). The pres- 
ent study shows that in the hematopoietic organ tenascin is 
a constitutive component of its ECM. The BM represents a 
constantly regenerating organ system containing stem cells. 
In two other stem cell containing organs, the skin and the 
intestine,  tenascin has  also been found to be strongly ex- 
pressed,  suggesting  a  possible  role  for tenascin  in  such 
proliferative systems,  Whereas the function of tenascin in 
skin and intestine is unknown and only speculative, we now 
provide evidence for an adliesive function of tenascin for he- 
rnatbpoietic progenitor cells in the human BM. 
The large disulfide-linked, six-armed molecular complex 
of tenascin shows a spider-like appearance in rotary shadow- 
ing (18). Each arm of this complex is formed by one subunit 
of tenascin which may vary in length due to differentially 
spliced mRNA variants. The subun'its show a modular struc- 
ture consisting of a  constant number Of EGF-like repeats, 
variant fibronec/in type HI-like repeats and a fibrinogen-like 
sequence. Two human splice variants corresponding to the 
six  and  eight  kb  messages  were  reported  (23,  31);  one 
subunit with all fifteen fibronectin type III repeats included 
("full length") and  another form which lacks  the type IN 
repeats 6-12.  Northern blot analysis for tenascin expression 
of the stromal cells in long term BM cultures also revealed 
two mRNA bands of six and eight kb. By sequencing differ- 
ent cDNA clones and using PCR analysis, however, addi- 
tional isoforms were reported by Siri et al. (41).  One splice 
variant  only  lacked  the  fibronectin  type  III  repeat  11, 
Table II. 
Cell attachment 
K562  HL60  KGIa  Bone marrow Cells 
Tenascin  +  +  +  +  +  +  +  +  .  +  + 
Fibronectin  + + +  +  +  + + + 
+ + +,  strong binding  (>1500 cells/ram  2) 
+ +,  intermediate binding  (500-1500  cells/ram  2) 
+, moderate binding  (100-500 cells/mm  2) 
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ted. The corresponding messages of these two additional iso- 
forms, however, could not be differentiated from the six and 
eight kb mRNA-related variants from the available Northern 
data. Thus, PCR analysis has to be performed to study the 
expression of additional  mRNA  isoforms in  BM  stromal 
cells. The protein data obtained from the immunoblot analy- 
sis  paralleled the  mRNA  data.  Two prominent bands,  a 
stronger band of ~o 280 kD and a weaker band of 220 kD, 
could be observed in extracts from BM stromal cells. This 
result is in accordance with the stronger expression of the 
8-kb message.  But again it is not possible to decide if the 
bands detected in the Western blot contain only one or more 
isoforms of tenascin. 
Using fragments of tenascin, it was convincingly demon- 
strated that the intact tenascin molecule contains two coun- 
teracting active sites within one subunit, a cell-binding site 
and one site responsible for an anti-adhesive signal (42). The 
functions of the various isoforms of tenascin are not known. 
However, the cell-binding site and the anti-adhesive site do 
not seem to be affected by the splicing process because the 
type IU repeats containing the binding sequence and the anti- 
adhesive sequence are not located within the splice region. 
Thus, both activities are present within one tenascin mole- 
cule and may be used in a cell-type and tissue-specific man- 
ner (10).  A  strong binding of the leukemic cell lines K562 
and HL60 and an intermediate binding of the cell line KGIa, 
which are  all thought to represent defined developmental 
stages, to purified tenascin could be observed. Unfraction- 
ated BM cells which, however, represent a mixture of many 
maturation stages, showed also an intermediate binding. It 
will  be  important to  determine exactly which  progenitor 
populations can interact with tenascin. Such an approach is 
feasible by FACS separation of BM cells. In the BM with its 
high turnover and constant migration of ceils, a strong bind- 
ing of the maturing hematopoietic cells to the microenviron- 
ment is not desired. The cells have to attach as well as to 
be  released  from  the  surrounding  matrix.  The  observed 
correlation between tenascin and fibronectin expression in 
the extracellular network of native BM sections may indicate 
that binding strength could be regulated by an interaction of 
tenascin and fibronectin. Fibroblasts can also attach to tenas- 
cin,  but  tenascin  is  also  able  to  inhibit  cell  binding  to 
fibronectin, an effect which can be shown for fibroblasts as 
well as for monocytes (12, 35). In addition to the attachment 
assay using purified tenascin, our antibody inhibition assay 
for cell binding between hematopoietic progenitor cells and 
the matrix produced by microenvironmental stromal cells 
also demonstrated that tenascin has binding properties, al- 
beit only moderate for myelomonocytic  progenitor cells. But 
it is clear that tenascin is not the only component responsible 
for this cell adhesion, and other matrix or cell adhesion mol- 
ecules are certainly also involved in this process. 
In addition to fibronectin, there is also a codistribution of 
tenascin seen in BM cryostat sections with collagen type III 
fibers. These interstitial fibers are thought to play a role in 
the mechanical stability of the tissue, whereas the noncol- 
lageneous components fibronectin and tenascin might coor- 
dinate cell adhesion and migration.  Tenascin can also be 
found in the walls of the blood vessels consistent with previ- 
ous studies which have documented an association of tenas- 
cin expression with smooth muscle cells (1, 29). 
Only sparse information is available concerning possible 
cellular receptors for tenascin. In a previous report, a mem- 
ber of the Bl-integrin family has been suggested to act as a 
cell-membrane bound tenascin ligand (4). In BM cryostat 
sections, an exact congruence of the Bl-integrin chain and 
tenascin expression was not detected, but this observation 
does not rule out that a member of the Bl-integrins can act 
as a ligand on hematopoietic cells for tenascin in this tissue. 
There may be different receptors present for tenascin in the 
hematopoietic system. Another component which has been 
reported to bind to tenascin is syndecan, a transmembrane 
proteoglycan. Different forms of syndecan exist, but only the 
mesenchymal syndecan with heparan sulfate glycosamino- 
glycan side chains interacts strongly with tenascin (38). Un- 
fortunately there are no data available concerning syndecan 
expression on stromal ceils. Analysis of this receptor type 
will reveal if a proteoglycan-tenascin interaction plays a role 
in the hematopoietic process. 
To date there is not much information about the specific 
attachment of the different committed progenitor cells and 
stem  cells  homing  to  the  BM  microenvironment.  Only 
hemonectin is  expressed in  the  BM  in a  tissue-restricted 
fashion and shows a lineage specificity for maturing granulo- 
cytes (7). Fibronectin and thrombospondin are also known 
to function as adhesive components in the BM, but the ubiq- 
uitous distribution of these components raises doubts about 
a specific involvement in progenitor cell binding.  Tenascin 
has a more restricted expression pattern than fibronectin but 
is also not specific for the BM. It may well be that combina- 
tions or interactions of different ECM components will lead 
to an appropriate specific microenvironment within the he- 
matopoietic system.  Attachment studies using  specifically 
enriched progenitor subpopulations with purified tenascin 
and combinations with other extracellular components will 
allow us to define more precisely the role of tenascin in the 
binding process of maturing hematopoietic cells. 
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